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cause of the illness. The PCR for amplification of a 470-bp 
fragment of citrate synthase gene was performed according 
to a previously published protocol (5). DNA was extracted 
with QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany) 
from whole blood and the crust of the eschar collected on 
day 5 of illness. In addition, serum samples were tested by 
indirect immunofluorescent assay for specific IgG and IgM 
against Francisella tularensis and Rickettsia spp. (spotted 
fever and typhus group) 5 days and 10 weeks after onset 
of fever.
Diagnosis of ATBF was affirmed by positive PCR re-
sult from the crust of the eschar; further sequence analy-
sis revealed the infection with R. africae. Serologic test-
ing demonstrated seroconversion of IgG to R. conorii and 
R. rickettsii, which cross-reacts with R. africae (negative 
immunofluorescent assay IgG titer at initial testing and 
1:1,024 for R. conorii and R. rickettsii 10 weeks later) (6). 
Thick and thin blood smears were negative for malaria.
ATBF is the second most well-established cause of 
febrile illness among travelers to sub-Saharan Africa, af-
ter malaria. Usually it manifests by fever (59%–100% of 
cases), headache (62%–83%), eschar (53%–100%), lymph-
adenopathy (43%–100%), and rash (15%–46%). The clini-
cal and laboratory findings in the patient reported here were 
similar to those previously reported among R. africae–in-
fected patients (1). In the acute phase of illness, a biopsy 
and culture from an eschar, as well as PCR, are the most 
suitable methods to confirm the ATBF diagnosis. In this 
case, ATBF was proven by PCR and subsequent sequenc-
ing from a crust sample but not from whole blood and se-
roconversion of IgG.
The first information about R. africae in ticks in Ugan-
da was published in 2013 by Lorusso et al. (7), but previ-
ously R. conorii also was found (8). The prevalence rate of 
R. africae infection among Amblyomma variegatum ticks in 
Uganda was 97.1% (9). Recently, Proboste et al. established 
the presence of previously undetected tickborne pathogens 
in rural dogs and associated ticks in Uganda. Tick species 
Haemaphysalis leachi, Rhipicephalus spp., and A. varie-
gatum were infected by Rickettsia spp. (18.9%), including 
R. conorii and R. massiliae; by Ehrlichia spp. (18.9%), in-
cluding E. chaffeensis; and by Anaplasma platys (10).
Our MEDLINE literature search found no previous 
descriptions of human R. africae infection in Uganda. This 
case indicates that ATBF should be included as a possible 
diagnosis in persons with febrile illness who have traveled 
to Uganda, a well-known tourist destination.
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To the Editor: Infections caused by carbapenem-resis-
tant Enterobacteriaceae have been associated with higher 
death rates than infections caused by carbapenem-suscepti-
ble strains, and resistant infections are mostly treated with 
polymyxins (1). Several outbreaks caused by carbapenem- 
and polymyxin-resistant Klebsiella pneumoniae (CPRKp) 
have been reported, mainly from Europe, and represent an 
emerging threat.
Carbapenem-resistant K. pneumoniae (CRKp) are en-
demic to Brazil, where polymyxin B (PMB) has been large-
ly used against infections caused by these microorganisms. 
We evaluated PMB resistance rates and clonal diversity 
among CRKp isolates from patients in São Paulo, Brazil. 
The study was approved by the Research Review Board of 
Fleury Institute in São Paulo.
All K. pneumoniae isolates, except those from urine 
and active surveillance samples, recovered from inpatients 
during January 1, 2011–December 31, 2015, at 10 private 
tertiary-care hospitals in São Paulo were included in the 
study. K. pneumoniae isolates were identified by matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry; we analyzed only the first isolate from each 
patient, unless other isolates were recovered after a 90-day 
interval. To determine antimicrobial drug MICs, we used 
nonautomated broth microdilution (2) polystyrene plates 
with cation-adjusted Mueller–Hinton broth (Becton Dick-
inson, Franklin Lakes, NJ, USA) for PMB and tigecycline; 
the Etest (bioMérieux, Marcy l’Etoile, France) for fosfo-
mycin; and the disk-diffusion method (3) for all other anti-
microbial drugs. Isolates with a MIC of <2 mg/L for PMB 
were considered susceptible; this value is the EUCAST 
(European Committee on Antimicrobial Susceptibility 
Testing) breakpoint for colistin in Enterobacteriaceae (2). 
Tigecycline and fosfomycin MICs were interpreted ac-
cording to EUCAST guidelines (2). Imipenem and me-
ropenem MICs were determined using the Etest for all 
isolates that were nonsusceptible to at least 1 carbapenem 
(ertapenem, meropenem, or imipenem) by disk-diffusion 
(3). We phenotypically detected class A carbapenemases 
as previously described (4).
We used convenience sampling to select 62 CPRKp 
isolates that were detected during 2014–2015 and used 
pulsed-field gel electrophoresis (PFGE) to evaluate 
their genomic DNA macrorestriction profiles after XbaI 
digestion. Dice similarity indexes were calculated using 
the UPGMA method with 1.25% tolerance and optimiza-
tion (5). The minimal Dice index for a clonal group was 
defined as 80%.
We performed multilocus sequence typing as de-
scribed (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.
html) for 11 isolates that represented the 2 major PFGE 
clonal groups, CPRKp1 and CPRKp2. The full bla
KPC
 nu-
cleotide sequence was determined for these isolates (online 
Technical Appendix Table 1, http://wwwnc.cdc.gov/EID/
article/22/11/16-0695-Techapp1.pdf).
We included a total of 3,085 K. pneumoniae isolates in 
the analysis (online Technical Appendix Table 2). A signifi-
cant increase in carbapenem resistance (p<0.001) was seen 
from 2011 (6.8%) to 2015 (35.5%) (Figure, panel A). Dur-
ing the last year of analysis, we detected K. pneumoniae 
carbapenemase (KPC) in 96.2% of CRKp isolates.
PMB MICs showed a bimodal distribution that was 
clearly differentiated by a 2 mg/L MIC (Figure, panel 
B). When we stratified MICs by year and carbapenem 
resistance, a significantly increasing trend of resistance 
was seen among CRKp isolates from 2011 (0%) to 2014 
(24.8%) to 2015 (27.1%) (p<0.001) (Figure, panel C). Re-
sistance among carbapenem-susceptible K. pneumoniae 
varied from 0.7% in 2011 to 3.9% in 2014 (p = 0.002).
We did not evaluate the mechanism of PMB resistance. 
However, this resistance in KPC-producing K. pneumoni-
ae is probably caused by the loss of mgrB function or the 
presence of nonsynonymous substitutions in pmrB that 
upregulate the pmrCAB and arnBCADTEF-pmrE operons, 
resulting in modification of lipid A. All these genes are lo-
cated on the bacterial chromosome. Susceptibility testing 
showed that amikacin and tigecycline were the most active 
non–β-lactam antimicrobial agents against CPRKp isolates 
(amikacin 73.8%, tigecycline 69.4%) and CRKp isolates 
(amikacin 79.9%, tigecycline 72.2%) (online Technical 
Appendix Table 3).
PFGE identified 2 major clonal groups. The largest 
group, CPRKp1 (n = 30), belonged to sequence type (ST) 
11, and the other group, CPRKp2 (n = 17), belonged to 
ST437. Both STs belonged to clonal complex (CC) 258. In-
terhospital and intrahospital dissemination among private 
and public hospitals was observed. All isolates tested had 
the bla
KPC-2
 gene (online Technical Appendix Figure).
In a previous study, the PMB resistance rate was 27% 
among 22 CRKp isolates from patients at a tertiary hospi-
tal in São Paulo during 2008–2010 (6). This rate is much 
higher than the rate we obtained for 2010, possibly because 
the previous study had a small number of isolates. CPRKp 
has been reported in various European countries at rates 
similar to those we report (7).
The predominance of CC258 among KPC-2-produc-
ing K. pneumoniae, but not among CPRKp, was reported 
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in Brazil (8), and ST11, a variant of ST258, has occasion-
ally been detected in colistin-resistant KPC-producing iso-
lates in Spain (9). The ST437 clone has been reported in 
KPC-2 producers in China (10), but we found no reports 
of CPRKp among this clonal group. Our findings show 
an alarming yearly increase in the rate of PMB resistance 
among CRKp isolates, mostly KPC-2 producing, and the 
occurrence of interhospital and intrahospital dissemination 
of CPRKp from CC258 in São Paulo.
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Figure. Antimicrobial resistance profile of Klebsiella pneumoniae 
isolated from hospital inpatients in São Paulo, Brazil. A) 
Carbapenem resistance trend among all K. pneumoniae isolates 
cultured during January 1, 2011–December 31, 2015 (n = 
3,085; p<0.001). B) Polymyxin B MIC distribution stratified by 
carbapenem susceptibility. C) Polymyxin B resistance trend 
stratified by carbapenem susceptibility, 2011–2015. B, C) 
Carbapenem-susceptible K. pneumoniae (CSKp) isolated during 
January 1, 2011–June 30, 2014 (n = 1,511) and carbapenem-
resistant K. pneumoniae (CRKp) isolated during January 1, 2011–
December 31, 2014 (n = 436); *during July 1, 2015–December 31, 
2015, only CRKp were tested for polymyxin B susceptibility (n = 
377). All statistical analyses were conducted using SAS Studio 3.4 
(SAS Institute, Inc., Cary, NC, USA). The statistical significance 
of a trend in resistance rates was evaluated using the χ2 test, in 
which p values <0.05 were considered significant: K. pneumoniae, 
p<0.001; CSKp, p = 0.004; CRKp, p = 0.003.
